EOLS
NASDAQ · Pharmaceuticals
Evolus Inc
$4.37
-0.06 (-1.35%)
Financial Highlights (FY 2026)
Revenue
299.90M
Net Income
-52,113,053
Gross Margin
66.3%
Profit Margin
-17.4%
Rev Growth
+26.0%
D/E Ratio
22.00
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 66.3% | 66.3% | 33.3% | 33.3% |
| Operating Margin | -11.0% | -9.9% | 33.6% | 33.3% |
| Profit Margin | -17.4% | -16.5% | 27.9% | 24.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 299.90M | 238.04M | 74.40M | 59.96M |
| Gross Profit | 198.92M | 157.89M | 24.80M | 19.98M |
| Operating Income | -32,959,068 | -23,544,060 | 24.98M | 19.96M |
| Net Income | -52,113,053 | -37,226,563 | 20.76M | 14.77M |
| Gross Margin | 66.3% | 66.3% | 33.3% | 33.3% |
| Operating Margin | -11.0% | -9.9% | 33.6% | 33.3% |
| Profit Margin | -17.4% | -16.5% | 27.9% | 24.6% |
| Rev Growth | +26.0% | +26.0% | +16.8% | +10.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 144.38M | 144.38M | 118.48M | 106.32M |
| Total Equity | 6.56M | 6.56M | 131.78M | 117.40M |
| D/E Ratio | 22.00 | 22.00 | 0.90 | 0.91 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -27,175,558 | -20,491,134 | 38.85M | 31.46M |
| Free Cash Flow | — | — | 15.01M | 10.49M |